Akademik Veri Yönetim Sistemi
Journal of the Turkish German Gynecology Association, cilt.7, sa.1, ss.63-67, 2006 (SCI-Expanded)
Levonorgestrel intrauterine system is originally developed for contraception. The levonorgestrel, released from an intrauterine system at rate of 20μg/24 hours, suppresses endometrial growth. This system provides a broad spectrum of noncontracetive health benefits including decreasing menstruel blood loss, reduction in symptoms of endometriosis and dysmenorrhea. Several trials revealed a reduction of menorrhagia in women using levonorgestrel intrauterine system as well as reduction of leiomyoma size. These results reduce the need for operative treatments and improve the quality of life. Most side effects and reasons for termination of hormone replacement therapy are related to the progestin component. But, hormone replacement therapy with the local delivery via levonorgestrel intrauterine system is effective in protecting the endometrium against hyperplasia, and will make withdrawal bleeding unnecessary. In this paper we review therapeutic use of the levonorgesterel system in non-contraceptional conditions.